Nonetheless, the efficacy of anlotinib in specific advanced lung cancer instances with BM is acknowledged, although cranial irradiation is presently considered the conventional treatment regimen for NSCLC patients lacking particular gene mutations or resistance to EGFR/ALK/ROS1-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.